Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

Publisher: La Merie Publishing
Pages: 204
Format: PDF
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0159
Release Date: July of 2018

800.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

This Competitive Intelligence report analyzes the competitive field of modulators of the tumor microenvironment via IDO & TDO, TGF-beta/R, CXCR4, novel chemokines, CSF-1R, CD47-SIRPalpha, adenosine pathway incl. CD73/CD39 and STING as of July 2018 in a tabulated format with structured listings of industry-relevant data. The report describes the lead indications of each unique molecule in the most advanced R&D stage. The mainly selective, but also bispecific new molecular entities modulate the tumor microenvironment by targeting

  • IDO (Indoleamine 2,3-dioxygenase
  • TDO (Tryptophan 2,3 dioxygenase)
  • TGF-β/R (Transforming Growth Factor beta/Receptor)
  • CXCR4 (Chemokine Receptor Type 4)
  • Novel Chemokines (e.g. CCR2; CCR4, CXCL2, CXCR2, IL-8)
  • CSF-1R (Colony Stimulating Factor-1 Receptor)
  • CD47 – SIRPα (Signal Regulatory Protein Alpha)
  • Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
  • STING (STimulator of INterferon Genes) Receptor
  • Others (e.g. arginase

At least 77 new molecular entities (NMEs) modulating the tumor microenvironment are in clinical development as monotherapy or in combination with checkpoint modulators or other active principles. At least 26 further NMEs are undergoing IND-enabling studies and numerous preclinical approaches are under evaluation.

The report includes a compilation of currently active projects in research and development of new molecular entities modulating the tumor microenvironment by targeting IDO & TDO, TGF-beta/R, CXCR4, novel chemokines, CSF-1R, CD47-SIRPalpha, adenosine pathway incl. CD73/CD39 and STING. In addition, the report lists company-specific R&D pipelines of modulators of the tumor microenvironment. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

Table of Contents:

1)        Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018
1a) IDO & TDO Inhibitors

  • First-Generation Selective IDO-1 Inhibitors
  • Novel Selective IDO-1 Inhibitors
  • Dual IDO/TDO Inhibitors
  • Selective TDO Inhibitors
  • Other Approaches for IDO or TDO Inhibition

1b) TGF-beta Inhibitors

  • Indirect TGF-beta Inhibition
  • Selective TGF-beta1 Inhibitors
  • Selective TGF-beta2 Inhibitors
  • Dual or Triple TGF-beta Inhibitors
  • Bispecific TGF-beta Inhibition

1c) CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors

  • CXCR4 Antagonists
  • CXCL12 / SDF-1 Inhibitors 

1d) Novel Chemokine Inhibitors & Chemokine Receptor Antagonists

  • Interleukin-8/CXCL8 Inhibitors & CXCR2/CXCR1 Antagonists
  • Other Interleukin Inhibitors
  • CCR2/CCR5 Antagonists
  • CCR4 Antagonists

1e) CSF-1R Antagonists & CSF-1 Inhibitors

  • Multi-Specific CSF-1R Tyrosine Kinase Inhibitors
  • Selective CSF-1R Antagonists and CSF-1 Inhibitors

1f) CD47 Antagonists & SIRPalpha Inhibitors

  • CD47 Antagonists
  • SIRPα Inhibitors
  • Bispecific CD47 Antagonists

1g) Adenosine Pathway Modulation

  • Selective Adenosine A2A Receptor Antagonists
  • Selective Adenosine A2B Receptor Antagonists
  • Dual Adenosine A2 Receptor Antagonists
  • CD73 Ectoenzyme Inhibitors
  • CD39 Ectoenzyme Inhibitors
  • Other Approaches

1h) STING Agonists

2)        Corporate Tumor Microenvironment Modulator R&D Pipelines



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top